Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.64 |
| ▸ | ABL1 | P00519 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.56 |
| ▸ | SMO | Q99835 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621834 | 0.83 | ABL1 (0.74) | PIK3CGPIK3CAABL1CYP3A4DYRK1A | |
| SCHEMBL1621112 | 0.82 | PIK3CG (0.79) | PIK3CGPIK3CACYP3A4SMO | |
| SCHEMBL1620345 | 0.81 | PIK3CA (0.74) | PIK3CGPIK3CACYP3A4DYRK1AFSCN1 | |
| SCHEMBL1622012 | 0.80 | PIK3CG (0.77) | PIK3CGPIK3CAABL1CYP3A4DYRK1A | |
| SCHEMBL1621634 | 0.79 | PIK3CG (0.67) | PIK3CGPIK3CAABL1CYP3A4DYRK1A | |
| SCHEMBL13188180 | 0.78 | PIK3CG (0.72) | PIK3CGPIK3CACYP3A4DYRK1ANPC1 | |
| SCHEMBL3141105 | 0.78 | PIK3CG (1.00) | PIK3CGPIK3CACYP3A4DYRK1ANPC1 | |
| SCHEMBL1621844 | 0.78 | PIK3CG (0.79) | PIK3CGPIK3CACYP3A4DYRK1ANPC1 | |
| SCHEMBL1621705 | 0.77 | PIK3CG (1.00) | PIK3CGPIK3CACYP3A4DYRK1ANPC1 | |
| SCHEMBL1621640 | 0.77 | PIK3CG (0.74) | PIK3CGPIK3CACYP3A4DYRK1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | claimed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | claimed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | claimed |
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | PIK3CG 5/4885PIK3CA 1/4885ABL1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.